Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections

Trial Profile

Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Bacterial infections
  • Focus Therapeutic Use
  • Acronyms TEAMM
  • Most Recent Events

    • 08 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 04 Nov 2016 Status changed from completed to active, no longer recruiting.
    • 03 Dec 2015 Accrual to date is 86% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top